SELARL GRANDE PHARMACIE DE TASSIGNY : revenue, balance sheet and financial ratios

SELARL GRANDE PHARMACIE DE TASSIGNY is a French company founded 10 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in FREJUS (83600), this company of category PME shows in 2020 a revenue of 4.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL GRANDE PHARMACIE DE TASSIGNY (SIREN 818504581)
Indicator 2024 2023 2022 2020 2019 2017
Revenue N/C N/C N/C 4 067 814 € 3 463 329 € 4 035 498 €
Net income 301 043 € 155 936 € 276 641 € 352 722 € 317 190 € 273 135 €
EBITDA N/C N/C N/C 559 552 € 502 115 € 442 705 €
Net margin N/C N/C N/C 8.7% 9.2% 6.8%

Revenue and income statement

In 2024, SELARL GRANDE PHARMACIE DE TASSIGNY generates positive net income of 301 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 273 k€ -> 301 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

301 043 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 106%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 39%. The balance between equity and debt is satisfactory.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

105.665%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

39.373%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

55.3%

Solvency indicators evolution
SELARL GRANDE PHARMACIE DE TASSIGNY

Sector positioning

Debt ratio
105.67 2024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average -13 pts over 3 years

In 2024, the debt ratio of SELARL GRANDE PHARMACIE D... (105.67) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
39.37% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average +12 pts over 3 years

In 2024, the financial autonomy of SELARL GRANDE PHARMACIE D... (39.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 142.75. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

142.753

Liquidity indicators evolution
SELARL GRANDE PHARMACIE DE TASSIGNY

Sector positioning

Liquidity ratio
142.75 2024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average -10 pts over 3 years

In 2024, the liquidity ratio of SELARL GRANDE PHARMACIE D... (142.75) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL GRANDE PHARMACIE DE TASSIGNY

Positioning of SELARL GRANDE PHARMACIE DE TASSIGNY in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of SELARL GRANDE PHARMACIE DE TASSIGNY is estimated at 4 202 782 € (range 2 926 751€ - 6 287 603€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
2926k€ 4202k€ 6287k€
4 202 782 € Range: 2 926 751€ - 6 287 603€
NAF 5 année 2024

Valuation method used

Net Income Multiple
301 043 € × 14.0x = 4 202 783 €
Range: 2 926 752€ - 6 287 604€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL GRANDE PHARMACIE DE TASSIGNY with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL GRANDE PHARMACIE DE TASSIGNY

What is the revenue of SELARL GRANDE PHARMACIE DE TASSIGNY ?

The revenue of SELARL GRANDE PHARMACIE DE TASSIGNY in 2020 is 4.1 M€.

Is SELARL GRANDE PHARMACIE DE TASSIGNY profitable?

Yes, SELARL GRANDE PHARMACIE DE TASSIGNY generated a net profit of 301 k€ in 2024.

Where is the headquarters of SELARL GRANDE PHARMACIE DE TASSIGNY ?

The headquarters of SELARL GRANDE PHARMACIE DE TASSIGNY is located in FREJUS (83600), in the department Var.

Where to find the tax return of SELARL GRANDE PHARMACIE DE TASSIGNY ?

The tax return of SELARL GRANDE PHARMACIE DE TASSIGNY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL GRANDE PHARMACIE DE TASSIGNY operate?

SELARL GRANDE PHARMACIE DE TASSIGNY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.